Clinical Trials for Non-Small Cell Lung Cancer

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial focuses on treatment-naïve patients with locally advanced or metastatic EGFR-mutated NSCLC (exon 19del or exon 21 L858R mutations) and investigates the effectiveness of enhanced versus standard dermatologic management in those treated with amivantamab, a bispecific antibody targeting EGFR and MET receptors, and lazertinib, an EGFR tyrosine kinase inhibitor.

ClinicalTrials.gov ID: NCT06120140

A Phase II Trial of Hepatic Ablation of Metastases to Modulate and Enhance Immunotherapy Response (HAMMER) in NSCLC

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial targets adults with stage IV NSCLC involving liver metastases, excluding those with EGFR or BRAF mutations and prior liver radiation, to evaluate the impact of adding liver stereotactic ablative radiotherapy (L-SABR) to a standard regimen of anti-PD-(L)1 based immunotherapy and optional platinum-based chemotherapy.

ClinicalTrials.gov ID: NCT05657873

A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial targets adult patients with advanced solid malignancies and evaluates the safety and efficacy of CRX100, an investigational immunotherapy combining autologous T cells and oncolytic vaccinia virus, as monotherapy and in combination with Pembrolizumab.

ClinicalTrials.gov ID: NCT04282044

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial targets adult patients with KRAS G12C mutant non-small cell lung cancer, evaluating the safety and efficacy of the combination of avutometinib, a dual RAF/MEK inhibitor, with sotorasib, with or without defactinib, for those with or without prior exposure to KRAS G12C inhibitors.

ClinicalTrials.gov ID: NCT05074810

First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients With Advanced/Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves patients with advanced/metastatic solid tumors, particularly those with non-small cell lung cancer (NSCLC) harboring EGFR mutations and/or cMET aberrations, who have exhausted standard treatments. It investigates EMB-01, a bispecific antibody targeting EGFR and cMET receptors, using EpimAb's FIT-Ig® platform, with weekly administrations in 28-day cycles.

ClinicalTrials.gov ID: NCT03797391

An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves adult patients with metastatic non-small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score of 50% or greater, comparing pembrolizumab, a PD-1 checkpoint inhibitor, combined with sacituzumab govitecan, a Trop-2 targeted antibody-drug conjugate, versus pembrolizumab monotherapy. Eligible patients must not have had prior systemic therapy for metastatic NSCLC and should not require targeted therapies for EGFR, ALK-1, or ROS-1 mutations.

ClinicalTrials.gov ID: NCT05609968

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves patients aged 18 and older with advanced solid tumors, including NSCLC, melanoma, pancreatic, and ovarian cancers, who have progressed after standard treatments or are treatment-naïve. It evaluates the safety and efficacy of ONC-392, an anti-CTLA-4 monoclonal antibody, alone and combined with pembrolizumab to determine appropriate dosing for future studies.

ClinicalTrials.gov ID: NCT04140526

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial is enrolling patients with various hematological malignancies, who have been previously treated with ibrutinib, to evaluate its long-term safety and efficacy and continue ibrutinib treatment; ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor.

ClinicalTrials.gov ID: NCT01804686

Pilot Study of a Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves adult patients with stage IV ALK-positive non-small cell lung cancer who have stable disease on ALK inhibitors, testing a peptide vaccine designed to stimulate T-cell responses to prevent resistance to ALK-targeted therapies.

ClinicalTrials.gov ID: NCT05950139

A Phase II Study of PCSK9 Inhibitor Alirocumab and PD-1 Inhibitor Cemiplimab in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung Cancer: TOP2201

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates the combination of alirocumab, a PCSK9 inhibitor, with cemiplimab, a PD-1 inhibitor, in patients with metastatic non-small cell lung cancer who have progressed after prior PD-1 therapies. It is aimed at those with specific molecular alterations such as EGFR, ALK, and ROS1, following progression on targeted treatments.

ClinicalTrials.gov ID: NCT05553834